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ABSTRACT
Sensory and cognitive impairments have been documented
in diabetic humans and animals, but the pathophysiology of
diabetes in the central nervous system is poorly understood.
Because a high glucose level disrupts gap junctional
communication in various cell types and astrocytes are
extensively coupled by gap junctions to form large syncytia,
the influence of experimental diabetes on gap junction
channel-mediated dye transfer was assessed in astrocytes in
tissue culture and in brain slices from diabetic rats.
Astrocytes grown in 15–25 mmol/l glucose had a slow-
onset, poorly reversible decrement in gap junctional
communication compared with those grown in 5.5 mmol/l
glucose. Astrocytes in brain slices from adult STZ (strepto-
zotocin)-treated rats at 20–24 weeks after the onset of
diabetes also exhibited reduced dye transfer. In cultured
astrocytes grown in high glucose, increased oxidative stress
preceded the decrement in dye transfer by several days, and
gap junctional impairment was prevented, but not rescued,
after its manifestation by compounds that can block or
reduceoxidative stress.Insharp contrast with thesefindings,
chaperone molecules known to facilitate protein folding
could prevent and rescue gap junctional impairment, even in
the presence of elevated glucose level and oxidative stress.
Immunostaining of Cx (connexin) 43 and 30, but not Cx26,
was altered by growth in high glucose. Disruption of
astrocytictraffickingofmetabolites andsignalling molecules
may alter interactions among astrocytes, neurons and
endothelial cells and contribute to changes in brain function
in diabetes. Involvement of the microvasculature may
contribute to diabetic complications in the brain, the
cardiovascular system and other organs.
Key words: astrocyte, connexin (Cx), diabetes, gap junction,
hyperglycaemia, streptozotocin.
INTRODUCTION
Many diverse, progressive and severe complications of
diabetes are well established and are linked to chronically
high glucose levels in conjunction with insulin deficiency
(Type 1 diabetes) or insulin resistance (Type 2 diabetes). The
complex, multifactorial pathobiology of diabetes (Brownlee,
2005) includes non-specific glycation reactions of glucose,
increased sorbitol production and osmotic stress, oxidative
stress due to generation of ROS (reactive oxygen species)/RNS
(reactive nitrogen species), depletion of endogenous anti-
oxidants, enhanced lipid peroxidation, metabolic changes,
altered hormonal responses, cardiovascular disease, kidney
damage, poor wound healing, and cataract formation.
Overall, the impact of diabetes on the central nervous system
is generally considered to be mild or modest compared with
involvement of peripheral organs and peripheral neuropathies
(Little et al., 2007), which have severe consequences for both
the quality and duration of life of diabetic patients.
Diabetes does, however, affect the brain, altering blood
flow, blood–brain barrier integrity, brain metabolism and
neurotransmitters, and cognitive function in diabetic patients
and in animal models, but these findings are sometimes
contradictory due, in part, to differences in duration, severity
and control of the disease and to methodological issues
(McCall, 1992, 2004, 2005; Mooradian, 1997; Allen et al.,
2004; Sima et al., 2004; Biessels and Gispen, 2005; Huber et
al., 2006; Kamal et al., 2006; Brands et al., 2007; DCCT/EDIC,
2007; Kodl and Seaquist, 2008; Manschot et al., 2008; Roberts
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asnneuro.org / Volume 2 (2) / art:e00030 57et al., 2008). Specific brain functions are measurably impaired
in diabetic patients, including increased latencies of visual
and auditory evoked potentials (Buller et al., 1988; Di Mario
et al., 1995; Dı ´az de Leo ´n-Morales et al., 2005) and hearing
deficits (Tay et al., 1995; Frisina et al., 2006; Vaughan et al.,
2006, 2007), all with unidentified aetiologies. Alloxan- and
STZ (streptozotocin)-treated diabetic rats have abnormal
visual and auditory evoked potentials (Buller et al., 1986;
Rubini et al., 1992; Biessels et al., 1999; Manschot et al.,
2003), impaired long-term potentiation and facilitated long-
term depression in hippocampal neurons, and abnormal water
maze learning skills (Biessels et al., 1998, Kamal et al., 1999,
2006; Biessels et al., 2005). Together, these findings suggest
that subtle or sub-clinical functional disturbances in diabetic
brain may be more widespread than generally recognized and
may affect auditory, visual and other sensory processing
pathways, as well as cognitive capability.
Our interest in the involvement of astrocytes in diabetic
complicationsof thecentralnervoussystem arose from reports
of impaired gap junctional communication in hyperglycaemic
vascular smooth muscle, endothelial cells and retinal pericytes
(Inoguchi et al., 1995; Stalmans and Himpens, 1997; Kuroki et
al., 1998; Oku et al., 2001; Sato et al., 2002; Li et al., 2003). We
recently found that astrocytes in the inferior colliculus, an
auditory pathway structure with the highest metabolic rate in
brain,arehighlycoupledbygapjunctions(Balletal.,2007)and
are involved in selective syncytial ‘trafficking’ of energy and
redox metabolites (Gandhi et al., 2009a), including lactate
(Gandhi et al., 2009b). (Note: in the present study, metabolite
‘trafficking’ refers to transfer among cells of small molecules
involved in metabolism, energetics and signalling by processes
driven mainly by concentration gradients. Trafficking of small
molecules involves diffusion and transporters, and differs from
protein ‘trafficking’. Fluorescent dyes are used as surrogate
markers to visualize and quantify movements of small
molecules among cells.) We hypothesized that diabetes may
cause ‘silent’ changes affecting astrocytic communication and
metabolite trafficking via gap junctions may alter interactions
among astrocytes, neurons and endothelial cells (i.e. the
neurovascular unit), thereby contributing to the slow,
progressive brain dysfunction in diabetes. The present study,
therefore, examined the effects of experimental diabetes on
astrocytic gap junctional transport using two model systems,
the STZ-diabetic rat and cultured astrocytes grown in medium
containing very high glucose concentrations.
Studies in rat models of diabetes show that plasma and
brain glucose levels increase on average by approx. 3-fold,
with mean values in brain rising from 2.2 mmol/g in controls
to 6.9 mmol/g in diabetic animals (Table 1). In STZ-diabetic
rats, the increases in plasma and brain glucose content occur
within 2 days after STZ treatment and persist for months at
levels similar to those in spontaneously diabetic rats (Table 1).
The rise in brain glucose concentration with an increase in
plasma glucose level is the expected consequence of
concentration gradient-driven transport of glucose across
the blood–brain barrier. Under steady state conditions in
normal rats infused with various concentrations of glucose,
the brain glucose level is approx. 20% that in plasma in the
normo- and hyper-glycaemic range; in contrast, the brain
plasma glucose distribution ratio falls during hypoglycaemia
when glucose supply does not match demand (Dienel et al.,
1991, 1997; Holden et al., 1991). Thus brain glucose level rises
when plasma glucose concentration increases, and in diabetic
rats the brain: plasma glucose distribution ratio is even
higher, approx. 50% greater than in control rats, and the
elevated ratio is not normalized by acute insulin treatment to
reduce plasma glucose level to the normal range (Hofer and
Lanier, 1991a, 1991b). Corresponding studies of brain glucose
level in human diabetics are sparse, but one NMR study
reported a 1.5-fold increase in the level of glucose relative to
creatine in diabetic brain and calculated a net rise in brain
glucose level of approx. 2 mmol/l (Table 1). Routine
commercially available tissue culture media contain glucose
concentrations as high as 25 mmol/l glucose, which
approximates to the level of glucose in the plasma of
diabetic animals and exceeds the normal and diabetic rat
brain glucose level by approx. 10- and 3-fold respectively
(Table 1). Astrocytes grown in ‘high’-glucose media would be
exposed to the myriad of well-established consequences of
severe, chronic hyperglycaemia, and the pathophysiological
consequences of neuronal and Schwann cell culture in high-
glucose media have been recently emphasized by Kleman et
al. (2008) and Mı ˆinea et al. (2002). In the present study,
astrocytes chronically exposed to elevated glucose levels in
vivo and in vitro were used as models of experimental
diabetes. We report that intercellular gap junction-mediated
communication among astrocytes is markedly reduced in
cultured cerebral cortical astrocytes and in slices of inferior
colliculus from STZ-treated rats, and that pharmacological
intervention can protect against or restore this impairment.
MATERIALS AND METHODS
Reagents
DMEM (Dulbecco’s modified Eagle’s medium; low glucose,
catalogue no. 12320-032, and high glucose, no. 12430-054),
penicillin, streptomycin, amphotericin B and trypsin were
obtained from Invitrogen (Carlsbad, CA, U.S.A.). FBS (fetal
bovine serum) was purchased from Hyclone (Logan, UT,
U.S.A.). dBcAMP (dibutyryl cAMP), L-LME (L-leucine methyl
ester hydrochloride), octanol, cytochalasin B, LYVS (Lucifer
Yellow VS, dilithium salt), LYCH (Lucifer Yellow CH, dilithium
salt), L-NAME (N
v-nitro-L-arginine methyl ester), 4-PBA (4-
phenylbutyric acid), glycerol, butyric acid and N-(methyl-
nitrosocarbamoyl)-a-D-glucosamine (STZ) were from Sigma–
Aldrich (St Louis, MO, U.S.A.). Rhodamine–dextran, 6-NBDG
{6-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-
glucose}, Alexa FluorH 350 carboxylic acid, succinimidyl ester
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drofluorescein) diacetate] and DCF-DA were from Invitrogen
(Molecular Probes, Eugene, OR, U.S.A.). TMAO (trimethylamine
N-oxide dihydrate) was from Acros Organics (Fisher Scientific,
Pittsburgh, PA, U.S.A.); TUDCA (tauroursodeoxycholic acid,
sodium salt), tunicamycin (Streptomyces lysosuperficus) and
MnTBAP [manganese(III) tetrakis(4-benzoic acid) porphyrin
chloride] were from Calbiochem (EMD Biosciences, La Jolla,
CA, U.S.A.). Affinity-purified rabbit polyclonal antibodies
against Cx43 (catalogue number 71-0700), Cx30 (71-2200)
and Cx26 (51-2800) and the goat anti-rabbit Texas Red-
labelled secondary antibody were from Invitrogen; goat
serum was from Dako (Carpinteria, CA, U.S.A.).
Astrocyte culture
Cultured astrocytes were prepared by small modifications of
established procedures (Hertz et al., 1998). Briefly, astrocytes
were harvested from the cerebral cortex of 1-day-old albino
Wistar–Hanover rats (Taconic Farms, Germantown, NY, U.S.A.)
Table 1 Plasma and brain glucose concentrations in experimental diabetes
BB/Wor, BioBredding/Worcester; Cr, creatine; Glc, glucose; STZ, streptozotocin.
(a)
Arterial plasma glucose (mmol/ml) Brain glucose (mmol/g)
Rat/duration/treatment Control Diabetic
Diabetic/
control Control Diabetic
Diabetic/
control Reference
2 Days/STZ 7.7* 27.7* 3.6 1.8 6.5 3.6 Folbergrova ´ et al.
(1992)
2–3 days/STZ 10.5* 28* 2.7 2.9 11.4 3.9 Ruderman et al.
(1974)
3 day/STZ 16.9 30.9 1.8 2.4 (CSF57.3
mmol/ml)
8.7 (CSF5
12.9
mmol/ml)
3.6 (CSF51.8
mmol/ml)
Shram et al.
(1997)
1 week/STZ 8.2 25.0 3.0 2.1 8.1 3.9 Hofer and Lanier
(1991a)
1 week/STZ 8.6 25.9 3.0 3.2 12.2 3.8 Lanier et al
(1996)
1 or 4 weeks/STZ 7.4{ 30.0{ (1
week);
16.3{
(4 weeks)
4.1 2.4 6.2 (1 and
4 weeks)
2.6 Mans et al.
(1988)
10 days/STZ 10.4 26 2.5 2.3 4.5 2.0 Garcı ´a-Espinosa
et al. (2003)
12 day/STZ; given insulin
for 8 days; assayed 4 days
after insulin withdrawal
7.6* 28* 3.7 1.7 6.6 3.9 Blackshear and
Alberti (1974)
2 weeks/STZ 9.4 24.7 2.6 1.2{ 2.2{ 1.8 Hoxworth et al.
(1999)
2 weeks/STZ 5.4 22.7 4.2 2.4 9.5 3.9 Wagner and
Lanier (1994)
6–8 weeks/STZ 11.3* 26.9* 2.4 ,2.3{ ,3.7{ (not
statistically
significant)
1.6 Tang et al.
(2000)
12 weeks/STZ 12.5 24.4 2.0 2.3{ 3.7{ 1.6 Puchowicz et al.
(2004)
Spontaneously diabetic
Wistar rat
7.6 23.6 3.1 1.7 7.6 4.5 Hofer and Lanier
(1991b)
20–28 weeks/ spontaneously
diabetic Zucker rat,
8.4*{ 38.9*{ 4.6 1.7 4.9 2.9 van der Graaf
et al. (2004)
BB/Wor diabetic Sprague–
Dawley rat
8 22 2.8 2.11 7.51 3.6 Jacob et al.
(2002)
Mean¡S.D. (n515) 9.3¡2.8 27.0¡4.2
(P,0.001)
3.1¡0.8 2.2¡0.5 6.9¡2.8
(P,0.001)
3.1¡1.0
(b)
Arterial plasma glucose (mmol/ml) Relative value (Glc/Cr)
Human Control Diabetic Diabetic/control Control Diabetic Diabetic/control Reference
Values 5.6–8.4* 13.9* 1.7–2.5 0.13||/0.12|| 0.21||/0.18|| 1.62 (parietal
cortex)/ 1.50
(occipital cortex)
Kreis and
Ross
(1992)
* Calculated from reported glucose level in whole blood by multiplying by the plasma/blood concentration ratio for glucose of 1.4 (Heath and Rose, 1969).
{ Blood drawn from inferior vena cava or tail vein.
{ Calculated from reported values of nmol/mg dry weight, assuming 1 mg dry weight/10 mg wet weight.
1 Values measured in microdialysate of extracellular fluid in the inferior colliculus.
|| NMR assays of glucose level relative to creatine in cerebral cortex; the authors calculated that the excess glucose level in diabetic brain was approx. 2 mmol/l.
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59and grown in T-75 culture flasks with DMEM containing 5.5
mmol/l glucose, 10% (v/v) FBS, 50 IU (international units) of
penicillin and 50 mg/ml of streptomycin at 37˚C in humidified
air containing 5% CO2. L-LME (0.1 mmol/l), a lysosomotrophic
agent that selectively destroys mononuclear cells including
microglia, was also included in the culture medium, and the
cultures were shaken by hand twice per week to remove
microglia. When confluent, the cells were trypsinized, seeded
on to polylysine-coated glass coverslips and grown to
confluence in a medium containing amphotericin B (2.5 mg/
ml). Then differentiation was induced by supplementing the
culture medium with 0.25 mmol/l dBcAMP. The next day, cells
were maintained in a medium containing 0.25 mmol/l
dBcAMP and 5.5, 15 or 25 mmol/l glucose for up to 4 weeks.
Purity of cultures was based on the expression of the
astrocyte marker, glial fibrillary acidic protein, which was
expressed in .90% of the cells.
STZ-induced diabetes
Male Sprague–Dawley rats (200–300 g; Harlan, Indianapolis,
IN, U.S.A.) were fasted overnight, injected intraperitoneally
with STZ (65 mg/kg body weight in 33 mmol/l citrate-
buffered saline, pH 4.5); controls received the same volume of
citrate-buffered saline (Romanovsky et al., 2006). Tail blood
samples were taken for glucose determination from over-
night-fasted animals on the day before STZ injection and on
days 3, 8 and 13 thereafter; rats were categorized as
normoglycaemic or hyperglycaemic, using a cut-off value of
.6.9 mmol/l to define hyperglycaemia based on the day 3
fasting blood glucose level. All animal use procedures were in
strict accordance with the NIH Guide for Care and Use of
Laboratory Animals and were approved by the local Animal
Care and Use Committee.
Brain slice preparation
At 20–24 weeks after induction of STZ-diabetes, the diabetic
and age-matched, vehicle-injected control rats were deeply
anaesthetized with halothane and decapitated and their
brains were quickly removed and chilled by immersion in an
oxygenated (i.e. bubbled with O2/CO2, 95:5), ice-cold aCSF
(artificial cerebrospinal fluid) solution (concentrations in
mmol/l: 26 NaHCO3, 10 glucose, 124 NaCl, 2.8 KCl, 2.0 MgSO4,
1.25 NaH2PO4 and 2.0 CaCl2, pH 7.3) and 248 sucrose, and
250 mm-thick slices were cut using a Leica (Heidelberg,
Germany) VT 1000S tissue slicer; inferior colliculus slices were
incubated in oxygenated aCSF containing sucrose for 30 min
at 35˚C and then for 1 h at 22˚C (Moyer and Brown, 1998).
Slices of inferior colliculus were transferred to an open bath
perfusion chamber (Warner Instruments, Hamden, CT, U.S.A.)
on the microscope stage. Then the slices of inferior colliculus
and the cultured astrocytes were perfused (1 ml/min) with
aCSF that was continuously bubbled with O2/CO2 (95:5) and
contained 26 mmol/l NaHCO3 (pH 7.3) and 10 mmol/l glucose
at approx. 21–22˚C.
Gap junction dye transfer assays
Two procedures were used to insert a membrane-impermeant
dye into astrocytes to assay gap junctional communication,
scrape-loading (el-Fouly et al., 1987; Giaume et al., 1991) and
diffusion into a single cell impaled with a micropipette (Ball
et al., 2007; Gandhi et al., 2009a). Scrape loading is
commonly used for dye transfer assays because it is a simple
procedure, but the procedure destroys cells at the scrape site
and releases their contents to the medium; it requires
medium changes and washing of cells after dye loading, and
it cannot be used in tissue slices in which astrocytes have
formed their syncytia during normal brain development
involving interactions of astrocytes with neurons and the
vasculature. Microinjection of cells is technically more
difficult, but offers more control for dye loading, and it can
be used in brain slices. Fluorescent compounds used to assay
dye transfer were LYVS (4% or 62 mmol/l), 4% LYVS plus 4%
LYCH, Alexa FluorH 350 (5 mmol/l) and 6-NBDG (20 mmol/l).
6-NBDG is a non-metabolizable fluorescent analogue of
glucose that is a substrate for glucose transporters. In the
brain slice assays of 6-NBDG gap junctional transfer, 10
mmol/l of cytochalasin B, a glucose transport inhibitor
(Speizer et al. 1985), was included to minimize efflux of 6-
NBDG from cells via glucose transporters. In these assays, an
excess amount of pyruvate (10 mmol/l) was added to the
perfusate as an oxidative fuel to compensate for blockade of
glucose transport.
Scrape loading
The procedure of Giaume et al. (1991) was used for scrape-
load assays, as follows. Glass coverslips containing astrocytes
were transferred tosterile 35 mmculture dishes; coverslips were
washed once and incubated in ionic-buffered solution
containing (concentrations in mmol/l) 130 NaCl, 2.8 KCl, 1
CaCl2, 2 MgCl2 and 10 Hepes (pH 7.2) for 1 min, washed again
and incubated in calcium-free medium for 1 min. The medium
was replaced with a calcium-free medium containing 0.5 mg/
ml LYVS and 1 mmol/l rhodamine–dextran (a non-permeant
macromolecule used to label the scrape-loaded cells); a 2–3
cm scrape was made with a razor blade, and dye transfer was
allowed for 2 min. Giaume et al. (1991) stated that calcium
was omitted from the medium during scrape-loading because
1 mmol/l Ca
2+ blocks Lucifer Yellow transfer; Mg
2+ was still
included in the scrape-load medium. A recent study showed
that incubation of cultured astrocytes in the nominal absence
of extracellular bivalent cations (Ca
2+ and Mg
2+)o p e n s
channels (hemichannels or pannexin channels) that allow
rapid, widespread entry of Lucifer Yellow into astrocytes (Ye
et al., 2003); the presence of Mg
2+ during the scrape-loading
would prevent opening of these channels. Cells were washed
twice with calcium containing ionic-buffered solution and
dye-labelled area determined at 8 min after scraping by
image analysis using MetaVue software. Line scans were
used to evaluate the change in Lucifer Yellow fluorescent
intensity as a function of distance from the scrape site. The
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scrape; regions were imaged, and gap junctional dye transfer
was calculated as the difference between the areas labelled
by LYVS (gap junction permeable) and rhodamine–dextran
(labels the dye-loaded cells); the mean value for each
triplicate determination was used as the area labelled in that
scrape-load assay.
Dye diffusion into single cells
For single-cell dye loading with micropipettes, cultured
astrocytes were visualized under DIC (differential interference
contrast) and astrocytes in brain slices were visualized under
IR-DIC (IR-differential interference contrast) (Dodt and
Zieglga ¨nsberger, 1990) using a Nikon Eclipse E600 microscope
(Nikon, Melville, NY, U.S.A.) equipped with a Nikon Fluor 640
[NA (numerical aperture)50.80] objective and Photometrics
CoolSNAP ES camera (Roper Scientific, Atlanta, GA, U.S.A.).
Micropipettes with 12–14 MV resistance (tip inner diameter:
1.0¡0.1 mm, outer diameter: 1.8¡0.1 mm; means¡S.D.)
were constructed from borosilicate glass (1 mm outer
diameter, 0.5 mm inner diameter) using a P97 pipette puller
(Sutter Instruments, Novato, CA, U.S.A.) and filled with a test
solution containing a fluorescent probe. Except where noted,
micropipette solutions contained (composition in mmol/l)
21.4 KCl, 0.5 CaCl2, 2 MgCl2, 5 EGTA, 2 ATP, 0.5 GTP, 2
ascorbate and 10 Hepes, pH 7.2, and one of three fluorescent
dyes (LYVS, excitation/emission maxima: 430/530 nm; 6-
NBDG, 475/550 nm; or Alexa FluorH 350, 346/442 nm). The
osmolarity of each solution was measured (Osmette II;
Precision Systems, Natick, MA, U.S.A.) and adjusted to 305–
320 mOsm/l with sucrose. Astrocytes were impaled with
micropipettes using an MP-225 manipulator (Sutter
Instruments, San Francisco, CA, U.S.A.), and tracers were
diffused into cells for 2 min in cultured cells and for 5 min in
brain slices. Fluorescence intensity was determined using
MetaVue software before (background) and after diffusion of
the test compound into a single astrocyte, and the dye-
labelled area was determined with MetaVue software (Ball et
al., 2007; Gandhi et al., 2009a). In brain slice assays, cells
labelled with LYVS were counted after cutting the 250 mm-
thick slices into 10 mm-thick serial sections; the number of
labelled cells was based on counts of the prominently labelled
nuclei. The area labelled by 6-NBDG in slices was measured in
the intact slice with MetaVue software. Gap junctional
transfer was inhibited by pretreatment with octanol (final
concentration, 0.6 mmol/l).
Dye transfer was also assayed in astrocytes cultured in
media containing 5.5 or 25 mmol/l glucose for up to 21 days
in the presence or absence of compounds to reduce ROS/RNS
levels or that facilitate protein folding. MnTBAP (50 mmol/l) is
a superoxide dimutase mimetic that is a scavenger of ROS
(Kowluru and Abbas, 2003) and L-NAME (1 mmol/l), a
competitive inhibitor of NOS (nitric oxide synthase) that
impairs formation of nitric oxide and RNS (Hink et al., 2001).
Chemical chaperones (Brown et al., 1996; Welch and Brown,
1996; O ¨zcan et al., 2006), 4-PBA (1 mmol/l), glycerol (25
mmol/l), TUDCA (25 mmol/l) and TMAO (100 mmol/l) were
added to the culture media at the time intervals indicated.
Tunicamycin (100 ng/ml, 16 h), an inhibitor of N-linked
glycosylation that causes ER (endoplasmic reticulum) stress,
served as the positive control for ER stress; butyrate (1 mmol/
l) was a control for 4-PBA. After cultured astrocytes were
treated for the time intervals indicated, LYVS transfer was
assayed by impaling a single astrocyte with a micropipette,
allowing the dye to diffuse for 2 min, and then the dye-
labelled area was measured using MetaVue software.
Oxidative stress assays
Astrocytes were grown in 5.5 or 25 mmol/l glucose in the
presence or absence of inhibitors or chaperones, and
‘oxidative stress’ was assayed with DCF-DA or carboxy-DCF-
DA, compounds that are cell membrane permeable, cleaved
by intracellular esterases and, after oxidation by various
reactive compounds, become fluorescent dichlorofluorescein
(DCF) or carboxy-DCF (Tampo et al., 2003; Cruthirds et al.,
2005 and references cited in these studies). At indicated days
in culture, DCF-DA (10 mmol/l) was added to the culture
medium (that had been changed 24 h earlier) or to a fresh
medium containing the inhibitors plus 30 mmol/l DCF-DA.
Cells were returned to the CO2 incubator for 30 min at 37˚C,
then washed with perfusion solution, and DCF fluorescence
intensity was measured with the Nikon E600 microscope
(640 objective) and MetaVue software. Ten field-of-view
images were collected per coverslip, and analysed by
thresholding to include the pixels with the highest 30% or
highest 2% fluorescence intensity; the 30% threshold value
excluded background fluorescence and included the cell
bodies plus ‘hot spots’, whereas the 2% threshold included
only the highest-intensity ‘hot spots’. Slices of inferior
colliculus from diabetic rats were incubated for 30 min in
10 mmol/l carboxy-DCF-DA and fluorescence intensity
assayed as described above.
Cx immunostaining
Cultured astrocytes on coverslips were fixed with 2% (w/v)
paraformaldehyde in 0.1 M PBS for 10 min, washed three
times with PTX (0.1 M PBS containing 0.3% Triton X), blocked
in 10% (v/v) goat serum in PTX for 30 min, and incubated
with rabbit polyclonal primary antibodies (diluted in 10%
goat serum in PTX as follows: Cx43, 1:250 to a final
concentration of 1 mg/ml; Cx30, 1:250, to 1 mg/ml; Cx26,
1:25, to 5 mg/ml) for 2 h at room temperature (approx. 21–
22˚C) and then overnight at 4˚C. The manufacturer’s
recommended levels for use in frozen sections were 1–5
mg/ml for Cx43 and Cx30 antibodies and 10–20 mg/ml for
Cx26; in the present study, the dilution of Cx43 was the same
as that used by Ye et al. (2003). The next day, samples were
warmed to room temperature, washed with PTX (three 5 min
washes), incubated with goat anti-rabbit secondary antibod-
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61ies conjugated to Texas Red (diluted 1:500 in 10% goat serum
in PTX) for 1 h at room temperature, given three 5-min
washes with PTX and stored at 4˚C in PBS. Immunostained Cx
protein includes intracellular punctate or vesicle-like struc-
tures (probably ER, Golgi apparatus and cytoplasmic vesicles;
see Wolff et al., 1998 and references cited therein), that were
prominent in the images of immunoreactive Cxs under the
fixation and immunoassay conditions used in the present
study (see the Results section). The area of this punctate or
vesicular immunoreactive material was measured by image
analysis of composite images of z-stacks using the maximum
projection setting with a Nikon E600 microscope with
confocal attachments and a 660 water immersion objective
(NA 1.00) and MetaVue software. The minimal fluorescence
intensity threshold value was set to only include prominent
punctate or vesicle-like structures, and integrated morpho-
metric analysis was used to measure their total area in each
of the 16–36 cells per Cx group that were derived from two
independent cultures.
Statistics
Comparisons between two groups of independent samples
were made with two-tailed, unpaired t tests. Comparisons
among three or more groups of independent samples were
made with one-way ANOVA and Dunnett’s test for multiple
comparisons against the same control value or the Bonferroni
test for multiple comparisons among experimental groups.
P,0.05 was considered to be statistically significant. All
statistical analyses were performed with GraphPad PrismH
software, version 5.02 (GraphPad Software, La Jolla, CA,
U.S.A.).
RESULTS
Severe hyperglycaemia reduces dye transfer
through gap junctional channels
Transcellular spreading LYVS after scrape-loading of astrocytes
grown for 3 weeks in 5.5 mmol/l glucose greatly exceeded that
ofastrocytesgrownin25mmol/lglucose(Figure 1A).Linescan
analysis of Lucifer Yellow fluorescence intensity with distance
showed that overall LYVS fluorescence level was higher and
dye spread extended further from the scrape site in cells grown
in the lower glucose concentration (Figure 1B). The mean LYVS
intensity in the pixels closest to the scrape site (at 0.6 mm)
tended to be higher (P50.084) in the low-glucose cultures and
it reached a peak (,2600 fluorescence units) at 26–29 mm
from the scrape, whereas the high-glucose cultures had a
much lower mean maximal value (,1700 fluorescence units;
P,0.001) and a broader peak that was closer (7.7–20 mm) to
the scrape (Figure 1B). At 90–100 mm from the scrape the
fluorescence intensities in the low glucose group were still
22% higher (P,0.001) than in the higher glucose group. These
findings suggest that the lower dye levels and reduced dye
spread in severely hyperglycaemic astrocytes are not due to
differential release of Lucifer Yellow from cells during the
scrape load procedure via Cx ‘hemichannels’ or pannexin
channels. If these channels were preferentially open to the
medium in either group of cells, extensive dye labelling would
Figure 1 Growth of astrocytes in high glucose reduces gap junctional
communication
(A) Cultured astrocytes were grown in low or high glucose for 21 days, and gap
junctional transfer of LYVS (1 mmol/l) was assayed by dye transfer after scrape
loading. The scrapes are in the centre of each panel, and the scale bar (100 mm)
applies to both panels. (B) Line scan analysis (using a 100 mm bar and MetaVue
software) of Lucifer Yellow fluorescence as a function of distance from the
scrape; the white lines are the means for three assays and shaded areas
represent ¡1 S.D. (C) Dye-labelled area assayed in the absence (n515 for 5.5
mmol/lglucose;n59for25mmol/lglucose)orpresence(n54)ofoctanol(final
concentration0.6mmol/l,10 min) to block gap junctions;values are means and
vertical bars are 1 S.D. The Lucifer Yellow-labelled area was calculated as the
difference in areas labelled by Lucifer Yellow and rhodamine–dextran (1 mmol/
l), a gap junction-impermeant tracer that labels only the scrape-loaded cells.
***P,0.001; NS, not significantly different; ANOVA and the Bonferroni test.
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just adjacent to the scrape site, as observed (Figures 1A and
1B); this labelling would be readily detected by visual
observation because the LYVS causes prominent labelling of
nuclei.
The net area labelled by LYVS was calculated by
subtracting the area of the scrape-filled cells (i.e. area
labelled by the gap junction-impermeant tracer, rhodamine–
dextran) from that labelled by LYVS. Astrocytes grown in low
glucose had a 4-fold higher dye-labelled area than those
grown in high glucose (Figure 1C). Blockade of gap junctions
with octanol reduced the LYVS-labelled area (Figure 1C) to
the level of that labelled by rhodamine–dextran (results not
shown).
Prolonged exposure to high glucose is required to
reduce dye transfer
Glucose concentration in the culture medium did not affect
astrocyte viability, and astrocytes grown in 5.5, 15 and 25
mmol/l glucose had similar cell densities on days 3, 14 and 21
(results not shown), as illustrated in Figure 2 for representative
cultures grown for 2 weeks in 5.5 mmol/l (Figure 2A) or 25
mmol/l (Figure 2B) glucose. However, when gap junctional
communication wasassayed by impaling a singleastrocyte with
a micropipette and diffusing Lucifer Yellow into one cell, dye
spreading from the impaled cell was much greater in cells
grown for 3 weeks in 5.5 mmol/l glucose (Figure 2C) compared
with those grown in 25 mmol/l glucose (Figure 2D), confirming
the results of scrape-load assays (Figure 1).
Time in culture did not affect the area labelled by
Lucifer Yellow in astrocytes grown in low glucose, but
those grown in high glucose had a progressive decrease in
gap junctional communication (Figure 2E). Impaired LYVS
transfer had a slow onset, requiring approx. 3–5 days
exposure to 15 or 25 mmol/l glucose before a statistically
significant decrement was detectable. The time courses and
maximal inhibition for cells grown in 15 and 25 mmol/l
glucose were similar; the maximal decrement in gap
junctional communication was relatively stable at approx.
50% of that in the low-glucose cultures during the
interval from 7 to 21 days (Figure 2E).
Diffusion of a smaller fluorescent dye, Alexa FluorH 350,
among astrocytes was stable with time in the low-glucose
cultures, and it also exhibited a progressive fall in labelled
area in the high-glucose cultures (Figure 2F). There was a 5-
day delay before Alexa FluorH 350-labelled area was reduced
by high glucose, and the 50% decrement was stable between
7 and 21 days. Thus the two dyes had similar lag times,
temporal profiles and maximal reduction of labelled area,
suggesting that reduced dye transfer may not be simply due
to partial constriction of the gap junctional channel to block
the passage of larger molecules (Alexa FluorH 350 has a
molecular mass of 311 Da after hydrolysis of the succinimidyl
ester by water compared with 536 Da for the ionized form of
LYVS). Note that Alexa FluorH 350 does label a greater area
than the LYVS in the low-glucose cultures (e.g. P,0.01 on
day 1; compare Figures 2E and 2F); this is probably due
mainly to its high fluorescence quantum yield (the concen-
tration of Alexa FluorH 350 in the micropipette was 5 mmol/l
compared with 62 mmol/l for LYVS), and perhaps also to its
smaller size.
Dye transfer deficit is not restored by subsequent
glycaemic control
When astrocytes were grown in 15 or 25 mmol/l glucose for 2
weeks and then transferred to 5.5 mmol/l glucose for an
additional 2 weeks, LYVS spreading via gap junctions did not
recover. Dye transfer remained subnormal after either 7 or 14
days in the low-glucose media (Figure 3), indicating that the
acquired decrement in gap junctional communication could
not be reversed within 2 weeks by simply reducing the
glucose concentration in the culture medium.
Oxidative stress precedes impairment of gap
junctional communication
Because diabetes is associated with oxidative stress
(Brownlee, 2005), DCF fluorescence was assayed at intervals
after exposure of astrocytes to the high-glucose medium to
assess changes in the levels of ROS and RNS. Increased DCF
fluorescence was detectable after 1 day of exposure to high
glucose, with a progressive rise with time in culture
(Figure 4). Elevated ROS/RNS production preceded impair-
ment of gap junctional communication that became evident
only after 3–5 days of exposure to very high glucose
(compare Figures 2E, 2F and 4).
Focal oxidative stress
The high-glucose cultures had focal ‘hot spots’ of greater DCF
fluorescence intensities (quantified by thresholding the
highest 2% fluorescence values; see the Materials and
methods section) that averaged approximately twice those
of the overall mean intensities in the high-glucose cultures
(thresholded at 30%) at all time points (Figure 4). The hot
spots in the hyperglycaemic cultures also had quite large S.D.
values. In contrast, hot spots in the control cultures grown in
5.5 mmol/l glucose had fluorescence intensities closer to the
overall mean intensities (Figure 4).
Magnitude of oxidative stress is variable in culture
batches
In a replicate experiment (results not shown) in which
astrocytes were grown in high or low glucose for 1, 3, 7 or
14 days (n53–5 coverslips per group with 9–11 regions of
interest assayed per coverslip for a total of 44–70 regions per
group) the cells were incubated for 30 min in 30 mmol/l DCF-
DA, and at each time point, DCF fluorescence was statistically
significantly higher in cells grown in 25 mmol/l glucose
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63compared with those in 5.5 mmol/l glucose (P,0.001).
However, the mean DCF fluorescence intensities in the high-
glucose cultures were more similar to each other at each time
point, differing somewhat from the data set in Figure 4. The
high glucose/low glucose ratio of DCF values in the replicate
cultures was 1.86, 2.84, 2.04 and 2.67 at 1, 3, 7 and 14 days for
threshold at 30%, and 2.52, 4.02, 2.42, and 4.78 respectively
for the ‘hot spots’ quantified by thresholding at 2%. Thus the
high-glucosecultureshavehigherDCFfluorescencethanthose
grown in low glucose, but replicate assays can differ in
magnitude. For unidentified reasons, some astrocytes grown in
high glucose exhibited low DCF fluorescence at 14 days, but
they still had reduced trafficking of LYVS. Unfortunately, the
oxidative stress and gap junctional transfer assays do not
permit longitudinal studies on the same cells; the properties of
the cells before the assay are unknown.
Figure 2 Slow onset of dye transfer impairment in severely hyperglycaemic astrocytes
Representative DIC images of astrocytes grown in 5.5 mmol/l (A) or 25 mmol/l (B) glucose for 14 days; images of nuclei that were
stained with Hoechst dye are superimposed on the DIC images. Similar cell densities were found in the low-glucose (44¡8 cells per
field) and high-glucose (42¡15 cells per field) cultures when the numbers of nuclei were counted on day 14 in images of different
cultures in 15 random fields of view (i.e. 200 mm6200 mm with a 640 objective) per group. Dye-transfer was assayed by impaling a
single astrocyte in different groups of cells with a micropipette, the dye was diffused into the cell for 2 min and the labelled area was
measured (C–F). Representative images (C, D) illustrate diffusion of LYVS among astrocytes grown for 21 days in 5.5 mmol/l (C)o r2 5
mmol/l (D) glucose; arrows identify the impaled cell. The scale bars in (B) and (D) are 50 mm and also apply to images in (A) and (C).
Dependence of Lucifer Yellow-labelled area on duration of growth at various glucose concentrations (E). The respective number of
samples per group is as follows: 5.5 mmol/l glucose, n57, 17, 6, 12, 16, 21, 10 and 21 at 1, 3, 5, 7, 10, 14, 17 and 21 days; 15 mmol/l
glucose, n520, 20, 20, 18 at 3, 7, 14 and 21 days; 25 mmol/l glucose, n58, 18, 6, 14, 17, 21, 16, 23 at 1, 3, 5, 7, 10, 14, 17 and 21
days. Alexa FluorH 350 (A350)-labelled area declines with time in high-glucose-containing medium (F). The respective number of
samples per group at 1, 3, 5, 7, 10, 14, 17 and 21 days is as follows: 5.5 mmol/l glucose, n56, 6, 7, 12, 18, 13, 12 and 11; 25 mmol/l
glucose, n56, 8, 6, 12, 19, 12, 10 and 12. Cells in each experimental group were derived from at least three independent cultures.
Values are means and vertical bars represent 1 S.D.; bars that are smaller than the symbol are not visible. *P,0.05, **P,0.01,
***P,0.001, for the indicated comparisons using the unpaired, two-tailed t test for two groups, and ANOVA and Dunnett’s test for
multiple comparisons against the respective 5.5 mmol/l glucose group.
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and oxidative stress
The body weight of STZ-diabetic rats during the 13–20-week
interval after onset of diabetes averaged 53¡2% (n54) of
age-matched, vehicle-injected controls (n54), and at 20
weeks, the respective body weights were 268¡36 and
471¡19 g. At the time of assay for dye transfer and
oxidative stress, the arterial plasma glucose level in diabetic
rats was elevated 4.1-fold compared with controls (33.1¡5.2
and 8.0¡0.9 mmol/l respectively; P,0.001), whereas arterial
plasma lactate content was unchanged (2.2¡0.7 and
2.2¡0.4 mmol/l respectively). To verify that brain glucose
levels were also elevated in our STZ rats, the glucose
concentration was assayed in ethanol extracts of cerebral
cortex dissected from funnel-frozen brains of two STZ rats,
using previously described methods (Dienel et al., 2007). The
brain glucose concentrations were 8.2 and 6.8 mmol/g,
indicating that both plasma and brain glucose levels in the
STZ rats used in the present study were within the range of
the mean literature values tabulated in Table 1.
Dye transfer among gap junction coupled astrocytes was
assayed by dye diffusion into single astrocytes in slices of the
inferior colliculus from age-matched, vehicle-treated control
and STZ-diabetic rats. Both Lucifer Yellow and 6-NBDG had
greater dye labelling in slices from control rats (Figures 5A
and 5C) compared with those from STZ-treated rats
(Figures 5B and 5D). The number of LYVS-labelled cells was
7.7-fold higher in slices from control compared with diabetic
rats (Figure 6A), whereas the area labelled by the fluorescent
glucose analogue, 6-NBDG (342 Da), was 2.2-fold greater in
control compared with diabetic rat slices (Figure 6B). DCF
fluorescence in diabetic brain slices was 3.2 times that in
controls (Figure 6C). Thus gap junctional communication was
Figure 3 Glycaemic control does not reverse the deficit previously
acquired during growth in hyperglycaemic conditions
Cultured astrocytes were grown in medium containing the indicated glucose
concentrations for 14 days. Then the cells grown in 15 or 25 mmol/l glucose
were also cultured in medium containing 5.5 mmol/l glucose, and all cultures
continued for an additional 7 or 14 days. At the time intervals indicated, dye
transfer was assayed by impaling a single astrocyte with a micropipette,
dye was diffused into the cell for 2 min and labelled area was measured.
The respective number of samples/group at 21 and 28 days is as follows:
5.5 mmol/l glucose, n520 and 10; 15 mmol/l glucose, n510 and 10; and 25
mmol/l glucose, n520 and 10. Cells in each experimental group were derived
from at least three independent cultures. Values are means and vertical bars
represent 1 S.D.; when bars are not visible, they are smaller than the symbol.
*P,0.05, **P,0.01, ***P,0.001, for the indicated comparisons using ANOVA
and Dunnett’s test for multiple comparisons against the respective 5.5 mmol/l
glucose group.
Figure 4 Oxidative stress is detectable after 1 day of severe hyper-
glycaemia and remains elevated
Cultured astrocytes were grown in media containing 5.5 or 25 mmol/l glucose
for 14 days. ROS/RNS production was assayed by DCF fluorescence (30 min
incubation in 10 mmol/l DCFDA) and quantified using MetaVue software, with
thresholding to include either the highest 2% or 30% fluorescence
intensities; thresholding at 30% excluded the background and thresholding
at 2% quantified the small ‘hot spots’ that are readily visible in the images.
The values thresholded at 2% and 30% were similar for cells grown in 5.5
mmol/l glucose; comparisons between the cells grown in 5.5 or 25 mmol/l
glucose were made for each respective threshold value. Endogenous
fluorescence in the absence of DCF was 114¡3 (30% threshold) and
123¡5 (2% threshold) for cells grown in 5.5 mmol/l glucose for 3 or 7 days,
and slightly lower values were obtained for cells grown in 25 mmol/l glucose
(results not shown). These control values for endogenous fluorescence were
not subtracted from those in which DCF was added to assay NOS/ROS
production, indicating that generation of DCF fluorescence by reactive
species in low-glucose media is very low. The respective number of samples
per group at 1, 2, 3, 7 and 14 days is as follows: 5.5 mmol/l glucose, n530,
29, 30, 30 and 45; 25 mmol/l glucose, n520, 17, 29, 15 and 35. Each sample
represents analyses of images (200mm 6200 mm) of astrocytes grown on
coverslips; results are from up to ten images per coverslip and three to five
coverslips per group. Cells in each experimental group were derived from at
least three independent cultures. Values are means and vertical bars
represent 1 S.D.; when bars are not visible, they are smaller than the symbol.
***P,0.001, for the indicated comparisons using the unpaired, two-tailed t
test against the respective 5.5 mmol/l glucose group.
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65reduced and oxidative stress was increased in slices of the
inferior colliculus from diabetic rats at 20–24 weeks after STZ
treatment, as observed in cultured astrocytes that were
exposed to much higher glucose levels for short time intervals
(compare with Figures 2 and 4).
Pharmacological treatment can induce, prevent
or restore changes in gap junctional permeability
ER stress is associated with obesity, insulin resistance and
Type 2 diabetes, and treatment with chemical chaperones
that reduce ER stress normalizes many pathophysiological
consequences of Type 2 diabetes (O ¨zcan et al., 2004, 2006). A
toxin that induces ER stress, ROS/NOS blockers that can
reduce oxidative stress (Cruthirds et al., 2005) and chemical
chaperones known to facilitate protein folding (Welch and
Brown, 1996; O ¨zcan et al., 2006) were, therefore, tested for
their ability to cause, prevent or restore deficits in gap
junctional communication.
ER stress impairs gap junctional communication
TunicamycinisaninhibitorofN-acetylglucosaminetransferases
known to cause ER stress by blocking the formation of N-
glycosidic protein–carbohydrate linkages and preventing the
glycosylationofnewlysynthesizedproteinsintheER.Astrocytes
were grown for 2 weeks in low glucose and then treated with
tunicamycin for 16 h and dye transfer was assayed. The dye-
labelled area was reduced by tunicamycin to the low level
observed in vehicle-treated cells that were grown in high
glucose for 2 weeks (Figure 7A), i.e. the Lucifer Yellow-labelled
area was approx. 4000 mm
2 under both these conditions. For
comparison with these values, astrocytes grown in low glucose
for up to 3 weeks had a Lucifer Yellow-labelled area of approx.
15000 mm
2 (Figures 2 and 3) and the 2–3 week values for low-
glucose cultures from Figures 2 and 3 are included in
Figure 5 Reduced dye transfer among astrocytes in brain slices from STZ-
diabetic rats compared with controls
Gap junctional communication was assayed in slices of inferior colliculus
from age-matched, vehicle-injected controls (A, C) and STZ-diabetic rats at
20–24 weeks after the onset of diabetes (B, D). A single astrocyte was
impaled with a micropipette containing either Lucifer Yellow (A, B)o r6 -
NBDG (C, D), and the dye was diffused into the cell for 5 min. The Lucifer
Yellow was a mixture of LYVS (4 g/100 ml)+LYCH (4 g/100 ml). 6-NBDG (5
mmol/l) is a non-metabolizable fluorescent analogue of glucose. The scale
bars in (A, B) are 200 mm (imaged with a 610 objective), and those in (C, D)
are 40 mm (imaged with a 640 objective). Arrows in (C, D) indicate the
NBDG-containing micropipette.
Figure 6 Gap junctional communication and oxidative stress in brain slices
from control and STZ-diabetic rats
Dye transfer was assayed in slices of inferior colliculus from adult male rats at
20–24 weeks after the onset of STZ-induced diabetes and in age-matched,
vehicle-injected controls by impaling a single astrocyte with a tracer-
containing micropipette and diffusing the tracer for 5 min (for more details,
see the legend to Figure 5). (A) Cells labelled with LYVS+LYCH (n519, with 1
injection into each of 19 brain slices derived from 4 control rats and 19 slices
from four diabetic rats). (B) Area labelled with 6-NBDG (n520 injections into
ten slices from five control rats and 16 injections into eight slices from four
diabetic rats). Note that the NBDG-labelled areas were measured in slices
while viewing with a 640 objective because the area labelled in the STZ-rat
slices was difficult to determine with a 610 objective; the NBDG-labelled
area in the control rats was, therefore, probably underestimated (see Figure 5)
and the difference between control and diabetic rats is likely to be greater
than shown in (B). (C) Formation of ROS/RNS species in slices of inferior
colliculus from control (n510) and STZ-diabetic (n58) rats was assayed as
carboxy-DCF fluorescence. ***P,0.001, unpaired, two-tailed t tests.
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additional multiple statistical comparisons against the same
data sets, comparisons in Figures 7(A) and 7(B) were made
againstthevehicle-treatedcontrolgrowninhighglucoseorthe
no treatment group in the high-to-low glucose transfer assay.
ROS/RNS inhibitors and chemical chaperones are
protective in the presence of high glucose
Continuous 2-week treatment of cultured astrocytes grown
in high glucose with MnTBAP, a superoxide dismutase
mimetic, or with L-NAME, an inhibitor of NOS (alone or in
combination) prevented the high-glucose-induced decrement
in dye transfer (Figure 7A). Similarly, four chemically
different chaperone molecules (4-PBA, glycerol, TMAO and
TUDCA) also protected against dye transfer impairment,
whereas butyrate, a control for 4-PBA, did not (Figure 7A).
Chaperones, not ROS/RNS inhibitors, restore the acquired
deficit
Astrocytes were grown for 2 weeks in high glucose and then
transferred to the low-glucose medium containing vehicle or
other compounds for 7 days. The dye-labelled area in vehicle-
treated astrocytes remained at the low level (Figure 7B)
obtained for astrocytes previously grown in high glucose
(compare with Figure 3). Inclusion of MnTBAP or L-NAME in
the low-glucose medium did not restore gap junctional
trafficking (i.e. the dye-labelled area remained low), whereas
inclusion of two chaperones, 4-PBA and TUDCA, did improve
dye transfer and increased the labelled area (Figure 7B).
Oxidative stress is eliminated by transfer to low glucose
DCF fluorescence was elevated in cells grown in high glucose
for 3 weeks compared with those grown in low glucose.
However, when astrocytes were grown in high glucose for 2
weeks and then transferred to low glucose for an additional
week, the level of oxidative stress fell to that of cells
continuously grown in low glucose for 3 weeks (Figure 7C).
Thusthedecrementingapjunctionalcommunicationcausedby
prior exposure tohighglucose persists (Figure 7B, notreatment
group), even though oxidative stress is eliminated (Figure 7C)
by reducing the glucose level in the culture medium.
Effect of gap junction permeability modulators on
oxidative stress
The ROS/RNS blockers would be expected to improve gap
junctional communication by reducing or preventing the rise
Figure 7 Influence of ROS/NOS inhibitors and chemical chaperones on dye
transfer and DCF fluorescence
(A) Dye transfer after diffusion into a single cell for 2 min was assayed in
astrocytes grown in high glucose for 14 days in the presence of various
compounds that were added to the culture medium at the onset of culture in
high glucose or (B) after 2 weeks growth in high glucose, followed by culture
for 1 week in low-glucose medium that contained inhibitors or chaperones.
For reference, the dye-labelled area obtained in low-glucose cultures grown
for 2 weeks (results from Figure 2E) are included in (A), and that from low-
glucose cultures at 3 weeks (results from Figure 3) are included in (B).
However, statistical comparisons did not include these data to avoid
additional multiple comparisons against the same data sets in other Figures.
(C) DCF fluorescence was assayed in astrocytes after 3 weeks growth in low
or high glucose (Glc) or 2 weeks in only high-glucose media followed by 1
week in low glucose. DCF fluorescence was thresholded at 30% or 2% of
fluorescence intensity as described in the caption of Figure 4 to quantify the
overall response and ‘hot spots’ respectively. Values are means and vertical
bars represent 1 S.D. Statistical comparisons, denoted as NS, not significant;
*P,0.05; **P,0.01; ***P,0.001, were as follows. In (A), multiple
comparisons were made with ANOVA and Dunnett’s test against the
vehicle-treated 25 mmol/l glucose culture [n525, 13, 24, 22, 5, 15, 25, 12, 8
and 5 for the vehicle (0.1 mol/l PBS), MnTBAP (50 mmol/l), L-NAME (1 mmol/
l), MnTBAP (50 mmol/l)+L-NAME (1 mmol/l), tunicamycin (100 ng/ml for 16
h), butyrate (1 mmol/l), 4-PBA (1 mmol/l), glycerol (25 mmol/l), TMAO (100
mmol/l) and TUDCA (25 mmol/l) groups respectively]. In (B), comparisons
were made against the no-treatment group that was transferred from high to
low glucose (n520, 10, 10, 12 and 8 for the no treatment, MnTBAP, L-NAME,
4-PBA and TUDCA groups respectively). In (C), comparisons were against the
5.5 mmol/l glucose group (n530 for 21 day/5.5 mmol/l; n520 for 21 day/25
mmol/l; n530 for 14 day/25 mmol/l followed by 7 day/5.5 mmol/l).
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67in DCF fluorescence in cells grown in high glucose, whereas
the chaperone molecules would not be expected to alter
glucose-induced oxidative stress. To test these predictions,
DCF fluorescence was assayed in two independent experi-
ments using different batches of astrocytes that were grown
for 2 weeks in 25 mmol/l glucose in the continuous presence
of each of the test compounds shown in Figure 7(A) (n530–
40 samples per group per experiment). Unfortunately, the
results in the replicate assays were variable (results not
shown), and further work is required to identify factors that
influence the response of DCF fluorescence intensity to these
drug treatments.
Summary of results of pharmacological studies
Both prolonged exposure to high glucose and short-term
tunicamycin treatment impair astrocytic gap junctional
communication. In high-glucose cultures, oxidative stress is
detectable on day 1 (Figure 4), whereas the fall in dye transfer
becomes manifest at approx. 3–5 days (Figures 2E and 2F).
Transfer of cells from high- to low-glucose medium was
sufficient to reduce DCF fluorescence to control levels
(Figure 7C), but not restore dye transfer to normal within 2
weeks (Figure 3). ROS/RNS inhibitors could prevent this deficit
if included in the medium at the onset of exposure to high
glucose (Figure 7A), but could not improve the acquired deficit
that persisted in the low-glucose medium (Figure 7B).
Chaperone treatment could, however, restore the gap junc-
tional deficit in the presence of high glucose (Figure 7A), as
well as in the presence (Figure 7A) or absence (Figures 7B and
7C) of elevated DCF fluorescence. Thus prolonged antecedent
oxidative stress is linked to reduced gap junctional trafficking,
but reducing ROS/RNS levels after the onset of the deficit did
not restore dye transfer (Figure 3). In sharp contrast, the
persistent change in Cx function acquired by growth in high
glucose was ameliorated by four different chaperone mole-
cules that can improve protein folding
Immunoreactive Cx protein
All astrocytes exhibited immunostaining for Cx43, Cx30 and
Cx26, with the most intense immunoreactivity mainly in
intracellular material, as illustrated for astrocytes grown for 2
weeks in 5.5 mmol/l glucose (Figure 8, left column).
Intracellular immunostained Cx protein can include ER, Golgi
apparatus and cytoplasmic vesicles (Wolff et al., 1998 and
references cited therein), and punctate, vesicle-like intracel-
lular staining in astrocytes is evident in other studies (e.g. Ye et
al., 2003). The area of the immunoreactive punctate structures
in astrocytes grown in high glucose was reduced to approx.
50% and 25% of that in the low-glucose cultures respectively
for Cx43 and Cx30, whereas that for Cx26 was unaffected
(Figure 8, right column). Thus the morphological appearance
of immunoreactive Cx protein is selectively influenced by
medium glucose concentration, perhaps reflecting changes in
trafficking or turnover of these proteins.
DISCUSSION
Prolonged hyperglycaemia interferes with
astrocytic gap junctional communication
The two major findings of the present study are that chronic
hyperglycaemia and STZ-induced diabetes markedly reduce
gap junctional dye transfer among astrocytes and that the
impairment of gap junctional communication can be pre-
vented and rescued by pharmacological treatment with
compounds that reduce oxidative stress or improve protein
folding. Impaired transcellular communication had a slow
onset and, once established, it was poorly reversible by
Figure 8 Effect of hyperglycaemia on staining of immunoreactive Cx
proteins in cultured astrocytes
Composite z-stacks of confocal images (left column) of immunostained
astrocytes showed a low-intensity background and prominent staining of
punctate or vesicular immunoreactive material that appeared to be mainly
intracellular. This morphological appearance of immunostaining was evident
for Cx43 (A), Cx30 (B) and Cx26 (C) protein in astrocytes grown on coverslips
for 14 days in a medium containing 5.5 mmol/l glucose; the scale bar is 12.5
mm and applies to all panels. Areas of these immunostained punctate/
vesicular objects (right columns) are means (vertical bars represent 1 S.D.)
from the following numbers of objects per group: Cx43, 5.5 mmol/l: n5752
objects in cells on five coverslips; 25 mmol/l: n5884 objects in cells on five
coverslips; Cx30, 5.5 mmol/l: n51099 objects, five coverslips; 25 mmol/l:
n51177 objects, five coverslips; Cx26, 5.5 mmol/l: n5514 objects, four
coverslips; and 25 mmol/l: n5974 objects, five coverslips.
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three tracers of different sizes and charges (Lucifer Yellow,
Alexa FluorH 350 and 6-NBDG, a non-metabolizable glucose
analogue), and the scrape-loading assays indicate that it did
not arise from differential dye release by hyperglycaemic cells
via pannexin pores or Cx hemichannels (Figures 1–3). Because
increased DCF fluorescence preceded the onset of the decline
in gap junctional permeability by 3–5 days and ROS/RNS
blockers could prevent but not rescue the decrement
(Figures 4 and 7), damage arising from oxidative stress may
be a causative factor. Acute tunicamycin treatment generates
abnormal newly synthesized proteins, causes ER stress and
impairs dye transfer within 16 h without hyperglycaemia and
oxidative stress. However, results of our ongoing studies
indicate that expression of selected markers for ER stress is
delayed compared with onset of reduced gap junctional
communication in hyperglycaemic cultured astrocytes, sug-
gesting that gap junctional impairment may be an early,
relatively selective event in the pathophysiology of diabetes.
High glucose is sufficient to impair gap
junctional communication
The effects of chronic hyperglycaemia and complications of
diabetes are very complex, and relationships among patho-
physiology, threshold glucose level and cumulative exposure to
elevated glucose concentrations are very difficult to define.
However, tissue culture experiments demonstrate that severe,
chronic hyperglycaemia itself is sufficient to disrupt gap
junctional communication in astrocytes in the absence of
endocrine dysfunction and multiorgan interactions. Both of
our experimental model systems, cultured astrocytes and STZ-
rats, have high glucose concentration as a variable, but they
differ with respect to maximal glucose level, cumulative
exposure and effects of interactions among brain cell types
and among body organs. Cumulative exposure can be
expressed as the product of glucose concentration multiplied
by time, or the area undera plot ofconcentration as a function
of time. Different pathophysiological processes can be
expected to take place at various threshold levels of glucose
concentration. For example, glucose flux into the sorbitol
pathway will progressively increase as glucose concentration
rises above normal due to the high Km of aldose reductase for
glucose (,25 mM). The threshold concentrations and
cumulative exposure required to cause various effects of
elevated glucose (e.g. non-enzymatic glycation reactions,
oxidative stress and disruption of signalling pathways) are
unknown, but these effects could be expected to increase with
glucose level and duration of exposure (Mı ˆinea et al., 2002).
Brain glucose levels are lower than in peripheral tissues owing
to the restrictive transport properties of the blood–brain
barrier (Table 1), but diabetic patients live with the disease for
decades, facilitating cumulative CNS (central nervous system)
effects of chronic hyperglycaemia.
Growth of cultured cells under severely hyperglycaemic
conditions is a pathophysiological condition relevant to
diabetes. Commercially available tissue culture media can
contain glucose concentrations ranging from 0 to 25 mmol/l
and, for example, DMEM is formulated with 0, 5.56 or 25
mmol/l glucose, Ham’s nutrient mixtures can have 7, 10 or
17.5 mmol/l glucose and Neurobasal
TM medium (Brewer et al.,
1993) contains 25 mmol/l glucose. Even a ‘low-glucose’
medium, 5–6 mmol/l glucose, is approximately twice the
normal rat brain glucose concentration (i.e. approx. 2–3
mmol/g) and is equivalent to severe diabetes in rat brain
(Table 1). Growth of astrocytes in 22 mmol/l glucose reduces
both glucose and lactate oxidation by approx. 50% compared
with cells grown in 2 mmol/l glucose (Abe et al., 2006), and
would be expected to predispose astrocytes grown in high
glucose to increased glycolytic metabolism and greater
lactate release. In cultured neurons, the lactate dehydrogen-
ase isoenzyme pattern was not altered by medium glucose
level (5.5, 13.4 or 26.8 mmol/l; O’Brien et al., 2007), but
Kleman et al. (2008) emphasize the negative effects of high
glucose levels on the viability of cultured neurons and
neuronal responsiveness to the AMPK (AMP-activated protein
kinase) energy signalling system. High glucose may or may
not influence experimental outcome, but diabetic complica-
tions are, nevertheless, a concern for astrocytes and neurons
grown in high glucose, and it is important to re-evaluate the
results of such studies (e.g. 20 mmol/l glucose: Ye et al., 2001,
2003, 2009; McCoy and Sontheimer, 2010; 25 mmol/l
glucose: Sorg and Magistretti, 1991; Yu et al., 1993;
Takahashi et al., 1995; Itoh et al., 2003; Pellerin and
Magistretti, 2005, 1994; Chenal and Pellerin, 2007; and 50
mmol/l glucose: Bliss et al., 2004). Also, Methods sections in
published studies sometimes only identify the ‘generic’
culture medium (e.g. DMEM) without stating the glucose
level or other key constituents; ideally, the catalogue number
of the medium should be reported so its formulation is
available. The use of normal brain tissue glucose levels for
growth of cultured cells with twice-weekly feeding schedules
may also have nutritional complexities. For example, our
unpublished data (K.K. Ball, N.F. Cruz and G.A. Dienel) indicate
that astrocytes grown in 5.5 mmol/l glucose consume most of
the glucose within approx. 12–18 h, with release of lactate to
the medium; this lactate can be subsequently consumed as an
oxidative substrate, along with glutamine and other sub-
strates in the medium. Daily replenishment of glucose and
other nutrients and removal of lactate and other compounds
released to the culture medium may be necessary to control
levels of extracellular metabolites, but total medium
replacement could also negatively affect the cells due to
various ‘stresses’ associated with removal from the incubator
and medium change, e.g. shear stress to the surface of the
cells, transient loss of CO2 and buffering capacity, and
transient hypoxia and hypothermia.
Abnormal proteins and therapeutic potential
Covalent protein modification can arise from various causes
known to occur in diabetes, e.g. non-enzymatic glycation
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69reactions and formation of advanced glycation end-
products, protein carbonylation reactions, and altered
regulation of gene expression and signalling pathways
causing abnormal phosphorylation or nitrosylation states
(Bonnefont-Rousselot, 2002; Brownlee, 2005). The ability of
four different chaperone molecules that can facilitate protein
folding in other experimental systems to (i) prevent the decline
in dye transfer even in the presence of high glucose levels and
oxidative stress and (ii) rescue an established deficit (Figure 7)
suggests that changes to Cx proteins secondary to oxidative
stress may cause abnormal protein structure, folding, protein–
protein interactions or protein trafficking that may be
reflected by the morphological changes in intracellular
non-junctional immunoreactive Cx 43 and 30 protein
(Figure 8). Further work is required to evaluate the
contributions of these possibilities to altered non-junctional
immunoreactive material in diabetic astrocytes. Poor revers-
ibility of gap junctional communication after reversion to
low-glucose culture media (Figures 3 and 7B) underscores
the importance of continuous, strict glycaemic control in
diabetic patients. The effectiveness of treatment with
chaperones (Figure 7) that are already approved for human
use (e.g. 4-phenylbutyrate and TUDCA; O ¨zcan et al., 2006)
opens a therapeutic avenue to improve gap junctional
intercellular trafficking that is effective in the presence
of high glucose levels, oxidative stress and metabolic
disturbances.
Involvement of different Cxs in many cell types
during experimental diabetes
Dysfunction of any or all the three astrocytic Cxs (Cx43,
Cx30 and Cx26), as well as Cx-associated proteins, may
contribute to the functional deficit of gap junctional
trafficking of small molecules during experimental diabetes
and would be anticipated to affect transcellular commun-
ication via channels that comprise these Cxs in all body
tissues, not just brain. Because Cx30 channels are not
permeable to LYCH (Manthey et al., 2001), the abnormal
transfer of Lucifer Yellow may involve Cx43 and Cx26
channels that are permeant to this dye (Elfgang et al.,
1995). Cx43 may be a major ‘target’ of diabetes in
astrocytes, as well in other organs, as suggested by
previous studies in other cell types.
Gap junctional communication in a number of cell types is
inhibited by growth in high-glucose media ranging from 14
to 30 mmol/l for different intervals (1–9 days) compared with
cells grown in 5–5.5 mmol/l glucose, and decrements have
been documented in endothelial cells in the aorta (Inoguchi
et al., 1995, 2001), in the retina (Fernandes et al., 2004) and in
epididymal fat pads (Sato et al., 2002; Li and Roy, 2009), in
smooth muscle cells in aorta (Kuroki et al., 1998; Inoguchi et
al., 2001), in pigment epithelial cells in retina (Stalmans and
Himpens, 1997; Malfait et al., 2001), and in pericytes in retina
(Li et al., 2003). These studies have linked dye transfer deficits
to altered PKC (protein kinase C) signalling, increased
phosphorylation of Cx43, reduced Cx43 mRNA and protein
levels, low Cx43 plaque counts, and increased proteosome-
mediated degradation of Cx43. Consistent with the above
findings are reports that propagation of calcium waves is
inhibited in hyperglycaemic and PKC-activated retinal
pigment epithelial cells (Stalmans and Himpens, 1997), as
well as in PKC-activated astrocytes (Enkvist and McCarthy,
1992). In STZ-diabetic rats, dye transfer is reduced in acutely
isolated pericytes in retinal microvessels after 5–18 days of
diabetes (Oku et al., 2001). Also, the increased duration of
QRS waves in electrocardiograms from STZ-diabetic rats is
associated with increased phosphorylation of Cx43 that is
linked to activation of PKC, with either unchanged or reduced
Cx43 protein levels (Inoguchi et al., 2001; Lin et al., 2006,
2008; Howarth et al., 2008). However, in coronary endothelial
cells isolated from STZ-diabetic mice, Cx40 is a critical
element in loss of gap junction intercellular communication;
its levels are reduced, along with those of Cx37, but not Cx43,
and high glucose impairs capillary network formation in vitro
(Makino et al., 2008). Together, the above findings indicate
that gap junctional communication is abnormal in many
organ systems exposed to prolonged hyperglycaemia and
experimental diabetes, with tissue- and organ-specific
effects. The brain is generally considered to be affected by
diabetes to a lesser extent than peripheral organs, but gap
junctional trafficking among astrocytes, retinal cells and
endothelial cells is markedly reduced.
Roles of gap junctions in pathophysiology of
diabetes and Alzheimer’s disease
Gap junction-coupled astrocytes are involved in integration of
neurotransmission, energetics and blood flow at a local level,
and impaired syncytial communication by means of cytoplas-
mic signalling, redox and energy-related molecules can
contribute to brain dysfunction. For example, lack of
Ins(1,4,5)P3 signalling arising from mutations in Cx26 in non-
neuronal support cells in the cochlea is sufficient to cause
deafness (Beltramello et al., 2005), indicating that a sensory
loss associated with neurons can arise from dysfunction of
other cell types whose roles are required for processing of
sensory information. Gap junctions have important roles in
regulation of vascular function (Figueroa and Duling, 2009),
and the brain’s vasculature is surrounded by astrocytic endfeet
that are extensively coupled with each other by gap junctions
that facilitate long-distance dye transfer along the vasculature
when dye is diffused into a single astrocyte (Ball et al., 2007).
Thus it is likely that signals among cells within the
‘neurovascular unit’ that comprises neurons, astrocytes and
endothelial cells would be disrupted by impairment of gap
junctional communication between astrocytic processes and
their endfeet. As discussed above, hyperglycaemia induces
abnormalities in Cx proteins and signalling in astrocytes,
endothelial cells in different tissues, vascular smooth muscle
cells, and retinal pericytes. Microvascularpathology is common
to diabetes and Alzheimer’s disease (Luchsinger and Gustafson,
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levels of amyloid b-peptide and phosphorylated tau protein (Li
et al., 2007), hyperglycaemia exacerbates pathophysiological
changes and cognitive decline in pre-symptomatic Alzheimer’s
mice (Burdo et al., 2009), and aged Alzheimer model mice have
altered astrocytic networks (Peters et al., 2009). Taken
together, these findings suggest that impairment of astrocytic
gap junctional trafficking may contribute to the pathology of
the microvasculature in brain and, ultimately, to sensory and
cognitive decline in diabetes and Alzheimer’s disease. In
addition, involvement of abnormalities in gap junctional
communication in vascular endothelial and smooth muscle
cells and cardiac cells may underlie or contribute to
complications of diabetes in the cardiovascular system and
other organs.
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